Cargando…

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis

Transforming growth factor β receptor (TGF-β1R) and receptor tyrosine kinases (RTKs), such as VEGFRs, PDGFRs and FGFRs are considered important therapeutic targets in blocking myofibroblast migration and activation of idiopathic pulmonary fibrosis (IPF). To screen and design innovative prodrug to si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Rui, Xu, Jian, Yan, Rong, Liu, Huanbin, Zhao, Jingxin, Xie, Yuan, Deng, Wenbin, Liao, Weiping, Nie, Yichu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493029/ https://www.ncbi.nlm.nih.gov/pubmed/36160399 http://dx.doi.org/10.3389/fphar.2022.998245

Ejemplares similares

CoQ10 enhances the efficacy of airway basal stem cell transplantation on bleomycin-induced idiopathic pulmonary fibrosis in mice
por: Liu, Huanbin, et al.
Publicado: (2022)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials
por: Qu, Kai, et al.
Publicado: (2016)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Tandem mass tag-based proteomics analysis reveals the multitarget mechanisms of Phyllanthus emblica against liver fibrosis
por: Gong, Puyang, et al.
Publicado: (2022)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
por: Camelo, Ana, et al.
Publicado: (2014)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014)

Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products
por: Du, Yue, et al.
Publicado: (2022)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
por: Zhang, Tingwei, et al.
Publicado: (2022)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
por: Liu, Peipei, et al.
Publicado: (2021)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
por: Han, Meishan, et al.
Publicado: (2022)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2022)

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2022)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2023)

Multitarget Multiscale Simulation for Pharmacological Treatment of Dystonia in Motor Cortex
por: Neymotin, Samuel A., et al.
Publicado: (2016)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model
por: Wu, Xuening, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
por: He, Xiangjun, et al.
Publicado: (2023)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
por: Shen, Jiahui, et al.
Publicado: (2023)

Maimendong Decoction Improves Pulmonary Function in Rats With Idiopathic Pulmonary Fibrosis by Inhibiting Endoplasmic Reticulum Stress in AECIIs
por: Shen, Mengmeng, et al.
Publicado: (2020)

New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
por: Sestito, Simona, et al.
Publicado: (2018)

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
por: Almeleebia, Tahani M., et al.
Publicado: (2022)

Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors
por: El-Atawneh, Shayma, et al.
Publicado: (2022)

Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin
por: Goyal, Sameer N., et al.
Publicado: (2017)

Natural Xanthones and Skin Inflammatory Diseases: Multitargeting Mechanisms of Action and Potential Application
por: Gunter, Natalie Vivien, et al.
Publicado: (2020)

Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19
por: Alegría-Arcos, Melissa, et al.
Publicado: (2022)

Mailuoshutong pill for varicocele-associated male infertility—Phytochemical characterisation and multitarget mechanism
por: Lv, Dongfang, et al.
Publicado: (2022)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
por: Ge, Huizhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s48ocitbup1003uk0pi1n1mk3d